Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450119 | 0.94 | CXCR3 (0.55) | SMN1; SMN2CXCR3MEN1KMT2APSMD14 | |
| SCHEMBL453845 | 0.90 | CXCR3 (0.55) | SMN1; SMN2CXCR3HTR6MEN1KMT2A | |
| SCHEMBL449210 | 0.85 | CXCR3 (0.59) | CXCR3MEN1KMT2APDE10AALDH1A1 | |
| SCHEMBL452466 | 0.85 | POLB (0.58) | SMN1; SMN2CXCR3HTR6MEN1KMT2A | |
| SCHEMBL453380 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2CXCR3HTR6MEN1KMT2A | |
| SCHEMBL449346 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2TP53CXCR3MEN1KMT2A | |
| SCHEMBL451143 | 0.81 | CXCR3 (0.51) | SMN1; SMN2CXCR3HTR6MEN1KMT2A | |
| SCHEMBL450828 | 0.81 | POLB (0.58) | CXCR3MEN1KMT2APDE10AALDH1A1 | |
| SCHEMBL451852 | 0.81 | ALDH1A1 (0.45) | SMN1; SMN2CXCR3HTR6MEN1KMT2A | |
| SCHEMBL454573 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2TP53CXCR3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | claimed |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | claimed |
| US-8748440-B2 | Quinazolinone modulators of nuclear receptors | EXELIXIS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | SMN1; SMN2 4873/4885TP53 4381/4885CXCR3 741/4885 |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | SMN1; SMN2 4873/4885TP53 4381/4885CXCR3 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.